Small Interfering RNA (SiRNA) Market to Hit $964.17 Million by 2030 says Cognitive Market Research

Rhea-AI Summary

The Global Small Interfering RNA (SiRNA) Market is projected to reach $964.17 Million by 2030, with a CAGR of 8.6% from 2023 to 2030. Key insights show that liposome-based systemic therapy represents 52.01% of the market share. The cancer segment leads therapeutics with a 38.14% share, while research institutions account for 43.07% of applications. North America dominated the market in 2022 due to robust R&D activities. Significant partnerships, such as Silence Therapeutics with Hansoh Pharmaceutical, are accelerating market growth in the APAC region. The report emphasizes a focus on RNA functions and its therapeutic potential for various genetic disorders.

Positive

• Market projected to reach $964.17 Million by 2030.
• CAGR of 8.6% between 2023 to 2030.
• Liposome-based systemic therapy holds 52.01% market share.
• Cancer segment dominates therapeutics with 38.14% share.
• APAC region anticipated to show lucrative growth due to increased funding activities.

Negative

• None.

CHICAGO, Feb. 9, 2023 /PRNewswire/ -- The Global Small Interfering RNA (SiRNA) Market size is projected to be $964.17 Million by 2030 growing at a CAGR of 8.6% from 2023 to 2030, as per a recent study published by Cognitive Market Research. Companies operating in Small Interfering RNA (SiRNA) market are focusing on strategic collaboration to meet customer need for a simplified, faster development process. For instance, Arrowhead and Horizon have entered into a USD 700 Million deal to develop an RNAi drug.

Major findings during the study of the Small Interfering RNA (SiRNA) Market:

• Liposome-based systemic therapy is used to encapsulate different types of genetic payloads, including siRNA, mRNA, and saRNA as it is geared towards encapsulating a wide variety of nucleic acids. They are primarily composed of cationic lipids along with some other lipid ingredients. All these ingredients, when combined provide a stealth effect to the drug product as it circulates within the body
• In terms of therapeutics, the Cancer segment dominates the Small Interfering RNA (SiRNA) market. This can be attributed to siRNA being produced from the long dsRNAs and small hairpin RNAs with the help of enzyme dicer. It prevents the process of translation by degrading mRNA. This function of the siRNA is seen as one of the most critical therapeutic tools for the treatment of various genetic disorders, including cancer
• North America has dominated the SiRNA market in 2022 owing to the availability of strong R&D activities in the U.S. For instance, in March 2020, AstraZeneca collaborated with Silence Therapeutics to discover, develop and commercialize siRNA therapeutics
• APAC region will show a lucrative growth rate in coming years, which is due to the rise in the funding activities for research and development. For instance, in 2021, Silence Therapeutics PLC entered the Chinese market through a partnering deal with Hansoh Pharmaceutical Group Co. Ltd. that involves developing short interfering RNA (siRNA) drugs against three undisclosed targets. Further, the high growth can be attributed to Sino-Korean tie-up in siRNA therapeutics in 2021

Read Full Market Analysis Small Interfering RNA siRNA: by Product Type (Liposome Based Systemic Therapy, Nanoparticle-Based Systemic Therapy, Others); by Therapeutics  (Cancer, AIDS, Alzheimer's Disease, Parkinson's Disease, Others) by Application (Hospital, Research Institutions, Academic Institutions, Pharmaceutical and Biotechnology, Companies, Others); by Region (North America, Europe, Asia Pacific, Latin America and Middle East, and Africa) Global Industry Analysis, COVID-19 Impact, and Industry Forecast, 2018-2030

Snapshot:

Global Small Interfering RNA (SiRNA) Market	2022
Global Revenue (USD Million)	510.25
CAGR (2023 to 2030)	8.6 %
Key Product Type Share	Liposome Based Systemic Therapy:52.01%
Key Therapeutics Share	Cancer:38.14%
Key Application Share	Research Institutions:43.07%
Key Regional Share	North America:36.37%

 

Small Interfering RNA (SiRNA) Market Growth and Trends

Cell and gene therapy R&D partnerships are increasing in proportion of all partnerships. It has been analyzed that cell-based immuno-oncology therapies are an incredibly active area of clinical development, representing nearly 60% of clinical trials in cancer treatment. A growing understanding of RNA functions and their vital role in various diseases has promoted its potential therapeutic usage. Recently, therapeutics have shown a vast diversification from small-molecule drugs. siRNA therapeutics have captured the interest of researchers. For instance, Arrowhead Pharmaceuticals and Horizon Therapeutics have entered a global partnership and license agreement to develop the former's ribonucleic acid interference (RNAi) therapeutic. As per this deal, Arrowhead has to carry out all the activities related to the therapeutic's preclinical development. Horizon will obtain an exclusive global license for ARO-XDH and will oversee the clinical development and marketing of the therapeutic.

Moreover, the clinical application of siRNA to "silence" the expression of specific malignant genes can be used to treat both genetic and acquired diseases. Hence, Sanofi and Alnylam Pharmaceuticals, Inc. have announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize the development and commercialization of specific products for the treatment of rare genetic diseases.

With four agents already approved by FDA, many others are in the advanced stages of the drug development pipeline. This will stimulate siRNA drugs to become a standard modality of pharmacotherapy.

Read the Full Report with the Table of Contents and Consult with Author:

https://www.cognitivemarketresearch.com/small-interfering-rna-sirna-market-report

Small Interfering RNA (SiRNA) Market Report Scope

Small Interfering RNA (SiRNA) Market - Product Type Outlook (Revenue, USD Million, 2018–2030)

• Liposome Based Systemic Therapy
• Nanoparticle-Based Systemic Therapy
• Others

Small Interfering RNA (SiRNA) Market - Therapeutics Outlook (Revenue, USD Million, 2018–2030)

• Cancer
• AIDS
• Alzheimer's Disease
• Parkinson's Disease
• Others

Small Interfering RNA (SiRNA) Market - Application Outlook (Revenue, USD Million, 2018–2030)

• Hospital
• Research Institutions
• Academic Institutions
• Pharmaceutical and Biotechnology Companies
• Others

By Regions

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, UK, Italy, Spain, Russia, Rest of Europe)
• Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Columbia, Rest of Latin America)
• Middle East & Africa (GCC, Saudi Arabia, Turkey, Egypt, Rest of MEA)

List of Key Companies

• GE
• Thermo Scientific
• Arbutus Biopharma
• Sanofi Genzyme
• Sylentis
• Arrowhead Research
• AInylam Pharmaceuticals
• Genecon Biotechnologies
• Silent Therapeutics
• Horizon Discovery
• OPKO Health
• Others

Related Reports to Small Interfering RNA (SiRNA) Market:

• Global mRNA Vaccine Market to Hit $97.51 Billion by 2030

Global mRNA Vaccine market is expected to hit $97.51 billion by 2030, growing at a CAGR of 6.85%. mRNA is a biological substance given in a series of shots to protect the body from developing a disease. Recently, emerging and re-emerging infectious diseases are posing a public health threat across the globe. This era has witnessed a wave of severe contagious disease outbreaks, which have devastatingly impacted lives and livelihoods around the globe. Further, environmental changes, caused by intensive industry development due to globalization have impacted human health. It has stimulated a high prevalence of infectious diseases, which boosts the market of mRNA vaccines market.

• Global Gene Therapy Market to Reach $19.08 Billion by 2030

The global gene therapy market is projected to reach $19.08 billion by 2030, growing at a CAGR of 18.97%. Gene therapy is a kind of medical approach that treats or prevents disease by correcting the underlying genetic problem. It thus allows doctors to treat a disorder by altering a person's genetic makeup instead of using drugs or surgery.  The increase in research activities in the healthcare sector results in a surge of the gene therapy market.

Other Related Reports:

• Global DNA Sequencing Market to reach $43.36 Billion by 2030, growing at an impressive CAGR of 18.3%
• Global MicroRNA (miRNA) Market to be worth $3.60 Billion by 2030 and is expected to reach a CAGR of 15.8%
• Global RNA Therapeutics Market to hit $26.34 Billion by 2030 and is expected to reach a CAGR of 16.5%

Explore Other Healthcare Industry Reports Published by Cognitive Market Research

About Cognitive Market Research

Cognitive Market Research has evolved as one of the leading market research and consulting firms, providing services across multiple domains. Cognitive Market Research gathers and analyses data about customers, competitors, distributors, and other market actors and forces operating across the value chain. As a market research company, we gather  information about the target market and end-use industries to verify the entire journey of the product or service in the global market. It helps our readers understand the demand and viability of their product/service and how it might perform in the real world and help them to build business strategies accordingly.

Follow Us: LinkedIn
Blog: How Companies can Select the Best Market Research Firms?
Why Do Companies Need Market Research to Understand their Market?

How to Contact Us:

Nicolas Shaw
Global Sales Manager
Cognitive Market Research
Phone: USA: (+1) +1 312-376-8303 | Europe and UK: (+44) 20-8144-9523
Asia Pacific: (+852) 81930785 | India: (+91) +91 983-496-8611
Email: sales@cognitivemarketresearch.com
Web: https://www.cognitivemarketresearch.com
Athenaeum Subscription

Logo: https://mma.prnewswire.com/media/1989016/Cognitive_Market_Research_Logo.jpg 

View original content:https://www.prnewswire.com/news-releases/small-interfering-rna-sirna-market-to-hit-964-17-million-by-2030-says-cognitive-market-research-301742970.html

SOURCE Cognitive Market Research

FAQ

What is the forecast for the SiRNA market by 2030?

The SiRNA market is projected to reach $964.17 Million by 2030, growing at a CAGR of 8.6% from 2023.

Which segment leads the SiRNA therapeutics market?

The cancer segment leads the SiRNA therapeutics market with a share of 38.14%.

What is the market share of liposome-based systemic therapy in the SiRNA market?

Liposome-based systemic therapy accounts for 52.01% of the SiRNA market share.

How has North America performed in the SiRNA market?

North America dominated the SiRNA market in 2022 due to strong R&D activities.

What factors are driving growth in the SiRNA market?

Strategic partnerships and increased funding for R&D, especially in the APAC region, are driving market growth.